Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 7, 2007, Pages 815-821

  Bonnet, Eric ^a,b   Genoux, Annelise ^a   Bernard, Jacques ^b   Fauvel, Josette ^a   Massip, Patrice ^b   Perret, Bertrand ^a,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU PURPAN   (France)

Author keywords

Antiretroviral therapy; Apolipoprotein A V; Apolipoprotein C III; Apolipoprotein E; Dyslipidemia; HIV; Lipodystrophy; Pharmacogenomics; Protease inhibitors; Tumor necrosis factor (TNF )

Indexed keywords

APOLIPOPROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL THERAPY; DYSLIPIDEMIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY JOURNAL; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM DISORDERS; POLYMORPHISM, GENETIC; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447268893     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.140     Document Type: Review

References (42)

1. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond M, et al., and the Swiss Cohort Study. Atherogenic dyslipemia in HIV-infected individuals with protease inhibitors. Circulation 1999;100:700-5.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
3. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:63-70.
4. Bonnet E, Ruidavets JB, Tuech J, Ferrieres J, Collet X, Fauvel J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001;86:296-302.
5. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
6. Tape C, Kisilevski R. Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1990;1043:295-300.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P, Leroy A. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
8. Mallal S, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleosidic analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
9. Capeau J, Caron M, Vigouroux C, Cervera P, Kim M, Maachi M, et al. Lipodystrophies related to antiretroviral treatment of HIV infection. Med Sci 2006;22:531-6.
10. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscl Thromb Vasc Biol 2000;20:2625-32.
11. Riddle TM, Kuhel DG, Woolet LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissue, due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276:37514-9.
12. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-31.
13. Lenhard JM, Furline ES, Jain RG, Iittoop O, Orband-Miller LA, Blanchard SG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000;47:121-9.
14. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-88.
15. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
16. Miserez AR, Muller PY, Barella L, Schwieter M, Erb P, Vernazza PL, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinemia. AIDS 2001;15:2045-8.
17. Yang A, King MS, Han L, Isaacson JD, Mueller T, Grimm DR, et al. Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS 2003;17:2142-3.
18. Bard JM, Lassalle R, Capeu J, Bac-Ngohou K, Nazih-Sanderson F, Remy G, et al. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with protease-inhibitor-containing antiretrovtral therapy. J Antiviral Ther 2006;11:361-70.
19. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75: 384-90.
20. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995;15: 963-71.
21. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, et al. Apolipoprotein C-III, metabolic syndrome and risk of coronary artery disease. J Lipid Res 2003; 44:2374-81.
22. Dammerman M, Sanfkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 39 untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-6.
23. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyeridemia. J Clin Invest 1995;96:2601-5.
24. Shoulders CC, Grantham TT, North JD, Gaspardone A, Tomai F, de Fazio A, et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum Genet 1996;98:557-66.
25. Groenendijk M, Cantor RM, Blom NH, Rotter JI, de Bruin TW, Dallinga-Thie GM. Association of plasma lipids and apolipoproteins with the insulin response element in the apo C-III promoter region in familial combined hyperlipidemia. J Lipid Res 1999;40:1036-44.
26. Fauvel J, Bonnet E, Ruidavets JB, Ferrières J, Toffoletti A, Massip P, et al. Interaction between apo C-III variants and protease inhibitors contributes to high triglycerides/ low HDL levels in treated HIV-patients. AIDS 2001;15: 2397-406.
27. Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005;191:1419-26.
28. Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5 -1131T>C gene variation. Clin Chem 2006; 52:1914-9.
29. Merkel N, Loeffler B, Kluger M, Fabig N, Geppert G, Pannachio LA, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. J Biol Chem 2005;280:21553-60.
30. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004;45:2096-105.
31. Olivier M, Wang X, Cole R, Gau B, Kim J, Rubin EM, et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004;83:912-23.
32. Jakel H, Nowak M, Moitrot E, Dehondt H, Hum DW, Penacchio LA, et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004;279:45462-9.
33. Reue K, Leff T, Breslow JL. Human apolipoprotein C-III gene expression is regulated by positive and negative cis-acting elements and tissue-specific protein factors. J Biol Chem 1988;263:6857-64.
34. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge F, Dehondt H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003;278:17982-5.
35. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;35:1881-3.
36. Gervois P, Genoux A, Vu-Dac N, Pennachio LA, Rubin EM, Fruchart-Najib J, et al. Apolipoprotein AV is an inflammatory responsive gene linking systemic inflammation to hyperlipidemia wabstractx. Circulation 2003; 265:Suppl IV:1253.
37. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte dif ferentiation and insulin resistance. Lancet 2002;359: 1026-31.
38. Qian H, Hausman DB, Compton MM, Martin RJ, Della-Fera MA, Hartzell DL, et al. TNFalpha induces and insulin inhibits caspase 3-dependent apoptosis. Biochem Biophys Res Commun 2001;284:1176-83.
39. Mondal D, Larussa VF, Agrawal KC. Synergistic antiadipogenic effects of HIV type I protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. AIDS Res Hum Retroviruses 2001;17: 1569-84.
40. Maher B, Alfirevic A, Javier Vilar F, Wilkins EG, Park BK, Pirrohamed M. TNFα-promoter region polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16:2013-8.
41. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, et al. Tumor necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003;17:121-3.
42. Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Hervé R, Aquilina C, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 2005;8:287-92.